Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Temozolomide (compound)


PubChem
Name: temozolomide
PubChem Compound ID: 10012882
Molecular formula: C6H6N6O2
Molecular weight: 195.144 g/mol
DrugBank
Identification
Name: temozolomide
Name (isomeric): DB00853
Drug Type: small molecule
Synonyms:
Methazolastone; Temozolamide; Temozolomidum [Latin]; Temozolodida [Spanish]
Brand: Temodar, Temodal
Category: Antineoplastic Agents, Antineoplastic Agents, Alkylating
CAS number: 85622-93-1
Pharmacology
Indication: For the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.
Pharmacology:
Temozolomide is an imidazotetrazine deritave and an antineoplastic agent. It is a prodrug that has little to no pharmacological activity until it is hydrolyzed in vivo to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). After administration, temozolomide undergoes rapid, nonenzymatic hydrolysis at physiological pH to MTIC, which is the activ...
show more »
Mechanism of Action:
Temozolomide is not active until it is converted at physiologic pH to MTIC. It is suggested that MTIC then alkylates DNA at the N7 position of guanine, O3 position of adenosine, and O6 position of guanosine, with the most common site being the N7 position. This methylation of guanine residues lead to single and double-strand DNA breaks and subseque...
show more »
Absorption: Rapid and complete absorption in the gastrointestinal tract
Protein binding: 15%
Route of elimination: About 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces.
Half Life: Approximately 1.8 hours.
Clearance: 5.5 L/hr/m2
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
NatalizumabThe immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Targets


Enzymes